HUP0203669A2 - Renin inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents
Renin inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásukInfo
- Publication number
- HUP0203669A2 HUP0203669A2 HU0203669A HUP0203669A HUP0203669A2 HU P0203669 A2 HUP0203669 A2 HU P0203669A2 HU 0203669 A HU0203669 A HU 0203669A HU P0203669 A HUP0203669 A HU P0203669A HU P0203669 A2 HUP0203669 A2 HU P0203669A2
- Authority
- HU
- Hungary
- Prior art keywords
- carbon
- alkoxy
- hydrogen atom
- alkyl
- group
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002461 renin inhibitor Substances 0.000 title 1
- 229940086526 renin-inhibitors Drugs 0.000 title 1
- -1 hydroxymethyl- Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 230000008816 organ damage Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pyridine Compounds (AREA)
Abstract
Az (I) általános képletű vegyületek[mely képletben R1 jelentése adottesetben egy-három 1-5 szénatomos alkoxicsoporttal helyettesítettnaftilcsoport; R2 jelentése adott esetben egy-három azonos vagykülönböző halogén-, ciano-, 1-3 szénatomos alkoxi- és/vagynitrohelyettesítőt hordozó fenil- vagy benzilcsoport; R3 jelentésehidroxi-metil-, imidazolil-metil-, triazolil-metil-, H-[CH(OR4)]2-CH2-, vagy H-[CH(OR4)]2-CH2-O-CH2- vagy R3a-(CH2)k-[CH(OR4)]1-CH2-O-csoport; R3a jelentése hidrogénatom, hidroxil-, imidazolil-,triazolil-, 1-3 szénatomos alkoxi-, 1-3 szénatomos alkoxi-(2-3szénatomos alkoxi)-, hidroxi-(2-3 szénatomos alkoxi)-, 1-3 szénatomosalkil-amino- vagy di-(1-3 szénatomos alkil)-amino-csoport; R4jelentése hidrogénatom vagy 1-3 szénatomos alkilcsoport; k értéke 1vagy 2, ha R3 jelentése hidrogénatom, k értéke 0; 1 értéke 1 vagy 2]és gyógyászatilag alkalmas sóik restenózissal, glaukomával,szívinfarktussal, magasvérnyomással és szervi károsodásokkal, pl.szívelégtelenséggel és veseelégtelenséggel társult betegségekkezelésére és megelőzésére alkalmazhatók. A találmány kiterjed az (I)általános képletű vegyületek előállítására és ezeket taratlmazógyógyszerkészítményekre is. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99108199 | 1999-04-27 | ||
| PCT/EP2000/003555 WO2000064873A1 (en) | 1999-04-27 | 2000-04-19 | Renin inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0203669A2 true HUP0203669A2 (hu) | 2003-02-28 |
| HUP0203669A3 HUP0203669A3 (en) | 2003-12-29 |
| HU227764B1 HU227764B1 (en) | 2012-02-28 |
Family
ID=8238050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0203669A HU227764B1 (en) | 1999-04-27 | 2000-04-19 | Renin inhibitors, process for their preparation, pharmaceutical compositions containing them and their use |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US6376672B1 (hu) |
| EP (1) | EP1175400B1 (hu) |
| JP (1) | JP3808706B2 (hu) |
| KR (1) | KR100443684B1 (hu) |
| CN (1) | CN1147471C (hu) |
| AR (2) | AR018719A1 (hu) |
| AT (1) | ATE512949T1 (hu) |
| AU (1) | AU763718B2 (hu) |
| BR (1) | BR0010080B1 (hu) |
| CA (1) | CA2370888C (hu) |
| CO (1) | CO5170513A1 (hu) |
| CZ (1) | CZ302012B6 (hu) |
| DK (1) | DK1175400T3 (hu) |
| EG (1) | EG23979A (hu) |
| ES (1) | ES2366668T3 (hu) |
| GC (1) | GC0000251A (hu) |
| HK (1) | HK1045999B (hu) |
| HR (1) | HRP20010762A2 (hu) |
| HU (1) | HU227764B1 (hu) |
| IL (2) | IL146002A0 (hu) |
| JO (1) | JO2256B1 (hu) |
| MA (1) | MA26787A1 (hu) |
| MX (1) | MXPA01010934A (hu) |
| MY (1) | MY127894A (hu) |
| NO (1) | NO320803B1 (hu) |
| NZ (1) | NZ514981A (hu) |
| PE (1) | PE20010069A1 (hu) |
| PL (1) | PL199895B1 (hu) |
| PT (1) | PT1175400E (hu) |
| RS (1) | RS51156B (hu) |
| RU (1) | RU2213731C2 (hu) |
| TR (1) | TR200103095T2 (hu) |
| TW (1) | TWI224593B (hu) |
| WO (1) | WO2000064873A1 (hu) |
| ZA (1) | ZA200108735B (hu) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6376672B1 (en) * | 1999-04-27 | 2002-04-23 | Hoffmann-La Roche Inc. | Naphthalenylmethoxypiperidines as renin inhibitors |
| US6835686B2 (en) * | 2001-07-05 | 2004-12-28 | Millennium Specialty Chemicals | Catalyst system and process for rearrangement of epoxides to allylic alcohols |
| EP1519920A1 (en) * | 2002-06-27 | 2005-04-06 | Actelion Pharmaceuticals Ltd. | Novel tetrahydropyridine derivatives as renin inhibitors |
| US20040214832A1 (en) * | 2003-04-10 | 2004-10-28 | Cuiman Cai | Piperazine derivative renin inhibitors |
| KR20060007041A (ko) * | 2003-04-29 | 2006-01-23 | 액테리온 파마슈티칼 리미티드 | 신규의 3,4-이치환된 1,2,3,6-테트라하이드로피리딘 유도체 |
| TW200513461A (en) | 2003-10-01 | 2005-04-16 | Speedel Experimenta Ag | Organische verbindungen |
| AR045950A1 (es) * | 2003-10-09 | 2005-11-16 | Speedel Experimenta Ag | Compuestos derivados de piperazina, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos. |
| WO2005037317A2 (en) * | 2003-10-17 | 2005-04-28 | Cornell Research Foundation, Inc. | Mast cell-derived renin |
| DE602004022704D1 (de) * | 2003-11-26 | 2009-10-01 | Novartis Ag | 4-phenylpiperidinderivate als renininhibitoren |
| TW200613274A (en) * | 2004-07-09 | 2006-05-01 | Speedel Experimenta Ag | Organic compounds |
| PT1799199E (pt) | 2004-10-08 | 2012-07-03 | Novartis Ag | Uso de inibidores da renina para a prevenção ou tratamento da disfunção diastólica ou insuficiência cardíaca diastólica |
| GB0428526D0 (en) * | 2004-12-30 | 2005-02-09 | Novartis Ag | Organic compounds |
| GB0500784D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| EP1897879A3 (en) * | 2005-03-31 | 2008-06-11 | Speedel Experimenta AG | 2,4,5-substituted piperidines as renin inhibitors |
| CN101230060A (zh) * | 2005-03-31 | 2008-07-30 | 斯皮德尔实验股份公司 | 取代的哌啶 |
| WO2006103275A1 (en) * | 2005-03-31 | 2006-10-05 | Speedel Experimenta Ag | 3,4,5-substituted piperidines as renin inhibitors |
| TW200716622A (en) * | 2005-03-31 | 2007-05-01 | Speedel Experimenta Ag | Substituted piperidines |
| TW200722424A (en) * | 2005-03-31 | 2007-06-16 | Speedel Experimenta Ag | Substituted piperidines |
| EP1707202A1 (de) * | 2005-03-31 | 2006-10-04 | Speedel Experimenta AG | Organische Verbindungen |
| KR100963455B1 (ko) | 2005-05-27 | 2010-06-18 | 액테리온 파마슈티칼 리미티드 | 신규한 피페리딘 카르복실산 아미드 유도체 |
| GB0514203D0 (en) * | 2005-07-11 | 2005-08-17 | Novartis Ag | Organic compounds |
| JP2009512715A (ja) * | 2005-10-21 | 2009-03-26 | ノバルティス アクチエンゲゼルシャフト | レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ |
| CN101356156B (zh) * | 2005-11-14 | 2012-12-05 | 生命医药公司 | 天冬氨酸蛋白酶抑制剂 |
| KR20080086921A (ko) * | 2005-12-30 | 2008-09-26 | 노파르티스 아게 | 레닌 억제제로서의 ３,５-치환된 피페리딘 화합물 |
| EP1816122A3 (en) * | 2006-01-19 | 2007-09-19 | Speedel Experimenta AG | 3,4,5-substituted piperidines as therapeutic compounds |
| TW200804359A (en) | 2006-01-19 | 2008-01-16 | Speedel Experimenta Ag | Substituted 4-phenylpiperidines |
| TW200821303A (en) * | 2006-08-08 | 2008-05-16 | Speedel Experimenta Ag | Organic compounds |
| WO2008021552A2 (en) * | 2006-08-18 | 2008-02-21 | Duke University | Biased ligands and methods of identifying same |
| EP1908761A1 (en) * | 2006-10-04 | 2008-04-09 | Speedel Experimenta AG | Organic compounds |
| EP1911758A1 (en) * | 2006-10-04 | 2008-04-16 | Speedel Experimenta AG | Phenyl piperidine derivatives for use as renin inhibitors |
| KR101238479B1 (ko) | 2007-06-25 | 2013-03-04 | 노파르티스 아게 | 레닌 억제제로 사용하기 위한 ｎ５-(２-에톡시에틸)-ｎ３-(２-피리디닐)-３,５-피페리딘디카르복스아미드 유도체 |
| CA2699889A1 (en) * | 2007-11-02 | 2009-05-07 | Novartis Ag | 4,4-disubstituted piperdines |
| US10517839B2 (en) | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
| EP2488661B1 (en) | 2009-10-14 | 2014-12-24 | Oberbauer, Rainer | Acute kidney injury risk testing |
| WO2013045505A1 (en) | 2011-09-28 | 2013-04-04 | Novartis Ag | Biomarkers for raas combination therapy |
| EP2810644A1 (en) | 2013-06-06 | 2014-12-10 | Ferrer Internacional, S.A. | Oral formulation for the treatment of cardiovascular diseases |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4868181A (en) * | 1986-08-04 | 1989-09-19 | E. I. Du Pont De Nemours And Company | 1,4-dihydropyridine derivatives with calcium agonist and alpha1 -antagonist activity |
| DK231088D0 (da) | 1988-04-28 | 1988-04-28 | Ferrosan As | Piperidinforbindelser, deres fremstilling og anvendelse |
| DE3640475A1 (de) | 1986-11-27 | 1988-06-09 | Hoechst Sa Lab | Arzneimittel auf basis von derivaten des 3,4-diphenylpiperidins, die verwendung der derivate als arzneimittel sowie neue 3,4-diphenylpiperidinderivate und verfahren zu ihrer herstellung |
| DK0594618T3 (da) | 1991-06-24 | 1996-08-26 | Optische Ind De Oude Delft Nv | Indretning til måling af en persons respiration |
| WO1997003911A1 (de) | 1995-07-24 | 1997-02-06 | Railfix N.V. | Elektro-permanentmagnetsystem zum manövrieren von einer magnetischen insbesondere ferromagnetischen last |
| JP3648251B2 (ja) | 1995-09-07 | 2005-05-18 | エフ．ホフマン−ラ ロシュ アーゲー | 心及び腎不全を治療するための新規４−（オキシアルコキシフェニル）−３−オキシ−ピペリジン |
| WO1999012532A2 (en) * | 1997-09-08 | 1999-03-18 | F.Hoffmann-La Roche Ag | Piperidine derivatives against malaria |
| US6376672B1 (en) * | 1999-04-27 | 2002-04-23 | Hoffmann-La Roche Inc. | Naphthalenylmethoxypiperidines as renin inhibitors |
-
2000
- 2000-04-04 US US09/542,303 patent/US6376672B1/en not_active Expired - Fee Related
- 2000-04-19 NZ NZ514981A patent/NZ514981A/xx not_active IP Right Cessation
- 2000-04-19 DK DK00922651.5T patent/DK1175400T3/da active
- 2000-04-19 WO PCT/EP2000/003555 patent/WO2000064873A1/en active IP Right Grant
- 2000-04-19 AU AU42968/00A patent/AU763718B2/en not_active Ceased
- 2000-04-19 CA CA002370888A patent/CA2370888C/en not_active Expired - Fee Related
- 2000-04-19 JP JP2000613826A patent/JP3808706B2/ja not_active Expired - Fee Related
- 2000-04-19 BR BRPI0010080-3A patent/BR0010080B1/pt not_active IP Right Cessation
- 2000-04-19 PT PT00922651T patent/PT1175400E/pt unknown
- 2000-04-19 IL IL14600200A patent/IL146002A0/xx active IP Right Grant
- 2000-04-19 MX MXPA01010934A patent/MXPA01010934A/es active IP Right Grant
- 2000-04-19 TR TR2001/03095T patent/TR200103095T2/xx unknown
- 2000-04-19 TW TW089107377A patent/TWI224593B/zh not_active IP Right Cessation
- 2000-04-19 ES ES00922651T patent/ES2366668T3/es not_active Expired - Lifetime
- 2000-04-19 CZ CZ20013854A patent/CZ302012B6/cs not_active IP Right Cessation
- 2000-04-19 RS YUP-771/01A patent/RS51156B/sr unknown
- 2000-04-19 HU HU0203669A patent/HU227764B1/hu not_active IP Right Cessation
- 2000-04-19 HK HK02107639.0A patent/HK1045999B/zh not_active IP Right Cessation
- 2000-04-19 HR HR20010762A patent/HRP20010762A2/xx not_active Application Discontinuation
- 2000-04-19 KR KR10-2001-7013696A patent/KR100443684B1/ko not_active Expired - Fee Related
- 2000-04-19 AT AT00922651T patent/ATE512949T1/de active
- 2000-04-19 RU RU2001130163/04A patent/RU2213731C2/ru not_active IP Right Cessation
- 2000-04-19 PL PL353442A patent/PL199895B1/pl not_active IP Right Cessation
- 2000-04-19 CN CNB008068003A patent/CN1147471C/zh not_active Expired - Fee Related
- 2000-04-19 EP EP00922651A patent/EP1175400B1/en not_active Expired - Lifetime
- 2000-04-23 JO JO200063A patent/JO2256B1/en active
- 2000-04-24 EG EG20000523A patent/EG23979A/xx active
- 2000-04-25 MY MYPI20001771A patent/MY127894A/en unknown
- 2000-04-25 GC GCP2000632 patent/GC0000251A/en active
- 2000-04-25 PE PE2000000386A patent/PE20010069A1/es not_active Application Discontinuation
- 2000-04-26 CO CO00029975A patent/CO5170513A1/es not_active Application Discontinuation
- 2000-04-26 AR ARP000101954A patent/AR018719A1/es active IP Right Grant
-
2001
- 2001-10-17 IL IL146002A patent/IL146002A/en not_active IP Right Cessation
- 2001-10-23 ZA ZA200108735A patent/ZA200108735B/xx unknown
- 2001-10-25 NO NO20015206A patent/NO320803B1/no not_active IP Right Cessation
- 2001-10-26 MA MA26386A patent/MA26787A1/fr unknown
- 2001-12-18 US US10/023,679 patent/US6673931B2/en not_active Expired - Fee Related
-
2009
- 2009-02-25 AR ARP090100634A patent/AR070473A2/es active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0203669A2 (hu) | Renin inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP9600448A2 (hu) | Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk | |
| HUP0301120A2 (hu) | Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények | |
| HUP0002347A2 (hu) | Hidantoin-, oxazol- és pirrolszármazékok alkalmazása gyulladásos betegségek kezelésére alkalmazható gyógyszerkészítmények előállítására | |
| AU525094B2 (en) | 1-phenyl-2-aminoethanol derivatives | |
| HUP9802433A2 (hu) | 8-Azabiciklo[3.2.1]okt-2-én-származékok, eljárás előállításukra és alkalmazásuk | |
| HUP0101137A2 (hu) | Véralvadást gátló savamidin-származékok és gyógyászati alkalmazásuk | |
| HUP0002495A1 (hu) | VLA-4 Által közvetített leukocita adhéziót gátló dipeptidszármazékok és rokon vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| PT87700A (pt) | Process for the preparation of a new pyrazolopyridine compound | |
| HUP9701193A2 (hu) | N-(4-Aril-tiazol-2-il)-szulfonamid-származékok alkalmazása neurológiai rendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására, új származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
| HUP0002476A2 (hu) | Aminvegyületek, előállításuk és alkalmazásuk | |
| HUP9900851A2 (hu) | Benzotiofénszármazékok felhasználása véredény simaizom sejtek migrálásának inhibiálására alkalmas gyógyszerkészítmények előállítására | |
| HUP9801219A2 (hu) | Triciklusos N-acilezett benzazepin és benzoxazepinszármazékok, az ezeket tartalmazó gyógyszerkészítmények, eljárás előállításukra | |
| DE60107820D1 (de) | Neue verwendung von phenylheteroalkylamin-derivaten | |
| PA8432901A1 (es) | Compuestos de piridilpirrol | |
| CA2136553A1 (en) | 7-(2-aminoethyl)-Benzothiazolones | |
| NO20010487L (no) | Disubstituert maleimidforbindelse og farmasøytisk anvendelse herav | |
| UA26368A (uk) | Спосіб одержаhhя похідhих оксадіазолалкілпуриhу або їх фармацевтичhо прийhятhих кислотhо-адитивhих солей (варіаhти) | |
| NO961000L (no) | Piperidinderivater, fremgangsmåte for fremstilling derav og medikament og preparat inneholdende slike | |
| NO900697L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive acetamid-derivater. | |
| DK0583271T3 (da) | Arylmorpholin, fremstilling og anvendelse | |
| HUP9801751A2 (hu) | Benzopiránszármazékok, azok előállítása és alkalmazása, valamint ilyen származékokat tartalmazó gyógyszerkészítmények | |
| HUP0402033A2 (hu) | 2-Amino-4-piridil-metil-tiazolin-származékok alkalmazása az indukálható NO-szintetáz inhibitoraként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP9803028A2 (hu) | Ciklusos nitronok és az azokat hatóanyagként tartalmazó gyógyszerkészítmények | |
| HUP9900668A2 (hu) | Szulfamidsavszármazékok, N-acil-szulfonamidok és szulfonil-karbamát-származékok alkalmazása lipoproteinszintet csökkentő gyógyászati készítmények előállítására |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of definitive patent protection due to non-payment of fees |